MedTrace Logo

Prevention of Syncope Trial 6 - Atomoxetine in Vasovagal Syncope

NCT02500732 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2020-04-21

Study results available
· View outcomes & findings →

Summary

Objective: To determine if atomoxetine 40 mg bid (bis in die) in patients ≥18 years old with recurrent vasovagal syncope will better prevent syncope during tilt testing than placebo.

Conditions

  • Vasovagal Syncope

Interventions

DRUG

Atomoxetine

40mg PO the night before and the morning of the study tilt table test.

DRUG

Placebo

oral placebo capsule designed to blind the atomoxetine intervention

Sponsors & Collaborators

  • Cardiac Arrhythmia Network of Canada

    collaborator OTHER

  • University of Calgary

    lead OTHER

Principal Investigators

  • Satish R Raj, MD MSCI · University of Calgary

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2018-01-31
Completion
2018-03-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02500732 on ClinicalTrials.gov